Sage Rhino Capital LLC Purchases 1,538 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Sage Rhino Capital LLC boosted its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 14.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,840 shares of the company’s stock after buying an additional 1,538 shares during the quarter. Sage Rhino Capital LLC’s holdings in Takeda Pharmaceutical were worth $157,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its holdings in Takeda Pharmaceutical by 389.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 10,020 shares of the company’s stock worth $132,000 after buying an additional 7,972 shares during the period. US Bancorp DE lifted its stake in shares of Takeda Pharmaceutical by 21.2% in the fourth quarter. US Bancorp DE now owns 124,332 shares of the company’s stock worth $1,646,000 after acquiring an additional 21,744 shares during the period. Fisher Asset Management LLC bought a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $547,000. QRG Capital Management Inc. boosted its holdings in Takeda Pharmaceutical by 16.8% in the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company’s stock valued at $4,364,000 after acquiring an additional 47,490 shares during the last quarter. Finally, Lake Street Advisors Group LLC acquired a new stake in Takeda Pharmaceutical during the 4th quarter valued at approximately $139,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 3.0 %

Shares of NYSE TAK opened at $14.84 on Tuesday. The company’s 50 day moving average price is $13.44 and its 200-day moving average price is $13.89. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08. The company has a market capitalization of $47.22 billion, a P/E ratio of 37.10, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.